3-[(5-Chloro-2-hydroxyphenyl)methyl]-5-[4-(trifluoromethyl)phenyl ]-1,3,4-oxadiazol-2(3H)-one, BMS-191011: opener of large-conductance Ca(2+)-activated potassium (maxi-K) channels, identification, solubility, and SAR.
Compound 8a (BMS-191011), an opener of the cloned large-conductance, Ca2+-activated potassium (maxi-K) channel, demonstrated efficacy in in vivo stroke models, which led to its nomination as a candidate for clinical evaluation. Its maxi-K channel opening properties were consistent with its structural topology, being derived by combining elements from other known maxi-K openers. However, 8a suffered from poor aqueous solubility, which complicated elucidation of SAR during in vitro evaluation. The activity of 8a in in vivo stroke models and studies directed toward improving its solubility are reported herein. Enhanced solubility was achieved by appending heterocycles to the 8a scaffold, and a notable observation was made that inclusion of a simple amino group (anilines 8k and 8l) yielded excellent in vitro maxi-K ion channel opening activity and enhanced brain-to-plasma partitioning compared to the appended heterocycles.
Romine
Jeffrey L
JL
Bristol-Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, Wallingford, Connecticut 06492, USA. jeffrey.romine@bms.com
Martin
Scott W
SW
Meanwell
Nicholas A
NA
Gribkoff
Valentin K
VK
Boissard
Christopher G
CG
Dworetzky
Steven I
SI
Natale
Joanne
J
Moon
Sandra
S
Ortiz
Astrid
A
Yeleswaram
Swamy
S
Pajor
Lorraine
L
Gao
Qi
Q
Starrett
John E
JE
D000818:Animals; D001921:Brain / Q000378:metabolism; D018360:Crystallography, X-Ray; D005260:Female; D066298:In Vitro Techniques; D015640:Ion Channel Gating; D051036:Large-Conductance Calcium-Activated Potassium Channels / Q000502:physiology*; D015394:Molecular Structure; D009865:Oocytes / Q000187:drug effects / Q000502:physiology; D010069:Oxadiazoles / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology*; D018408:Patch-Clamp Techniques; D010949:Plasma; D051381:Rats; D011918:Rats, Inbred SHR; D012995:Solubility; D020521:Stroke / Q000188:drug therapy / Q000473:pathology; D013329:Structure-Activity Relationship; D014982:Xenopus laevis
C480883:3-((5-chloro-2-hydroxyphenyl)methyl)-5-(4-(trifluoromethyl)phenyl)-1,3,4-oxadiazol-2(3H)-one; D051036:Large-Conductance Calcium-Activated Potassium Channels; D010069:Oxadiazoles